In a study led by McMaster University, Eli Lilly’s dulaglutide (Trulicity®) reduced cardiovascular events and kidney problems in middle-aged and older people with type 2 diabetes. Called the REWIND trial, McMaster University reports on the results of this...
CNN writer Jacqueline Howard reports that a recent clinical trial reveals that Janssen’s canagliflozin lowers the risk of kidney failure. Diabetes influences kidney failure worldwide. Partially reported in the New England Journal of Medicine, the recent study...
The JAVELIN Renal 101 clinical trial is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell...
Biospectrum Asia National Cancer Centre Singapore and Lucence Diagnostics have completed a study utilizing CLEARScore™ to predict immunotherapy response for kidney cancer. Comprehensive immunotherapy response information represents a critical goal. Immunotherapy...
Onclive reports on recent data from the CheckMate-214 trial. They write that nivolumab (Opdivo) combined with low-dose ipilimumab (Yervoy) continued to demonstrate strong responses and a survival benefit at 30 months follow-up as a frontline treatment for patients...
As reported in MedicalXpress, the UK’s National Health Service (NHS) have turned down a combination therapy of two immunotherapy drugs targeting a certain type of advanced kidney cancer. The results of the Phase 3 clinical trial revealed that the drug combination was...
